Gilead Sciences Statistics

Total Valuation

Gilead Sciences has a market cap or net worth of GBP 137.70 billion. The enterprise value is 147.34 billion.

Market Cap	137.70B
Enterprise Value	147.34B

Important Dates

The last earnings date was Tuesday, February 10, 2026.

Earnings Date	Feb 10, 2026
Ex-Dividend Date	Dec 15, 2025

Share Statistics

Current Share Class	1.24B
Shares Outstanding	n/a
Shares Change (YoY)	n/a
Shares Change (QoQ)	-0.08%
Owned by Insiders (%)	0.10%
Owned by Institutions (%)	89.29%
Float	1.24B

Valuation Ratios

The trailing PE ratio is 21.78 and the forward PE ratio is 16.99.

PE Ratio	21.78
Forward PE	16.99
PS Ratio	6.29
PB Ratio	8.19
P/TBV Ratio	n/a
P/FCF Ratio	19.60
P/OCF Ratio	18.50
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 13.35, with an EV/FCF ratio of 20.97.

EV / Earnings	23.30
EV / Sales	6.69
EV / EBITDA	13.35
EV / EBIT	16.66
EV / FCF	20.97

Financial Position

The company has a current ratio of 1.55, with a Debt / Equity ratio of 1.13.

Current Ratio	1.55
Quick Ratio	1.23
Debt / Equity	1.13
Debt / EBITDA	1.73
Debt / FCF	2.70
Interest Coverage	11.54

Financial Efficiency

Return on equity (ROE) is 40.66% and return on invested capital (ROIC) is 26.86%.

Return on Equity (ROE)	40.66%
Return on Assets (ROA)	12.52%
Return on Invested Capital (ROIC)	26.86%
Return on Capital Employed (ROCE)	25.03%
Weighted Average Cost of Capital (WACC)	6.03%
Revenue Per Employee	1.29M
Profits Per Employee	371,937
Employee Count	17,000
Asset Turnover	0.50
Inventory Turnover	3.58

Taxes

In the past 12 months, Gilead Sciences has paid 955.50 million in taxes.

Income Tax	955.50M
Effective Tax Rate	13.13%

Stock Price Statistics

The stock price has increased by +29.70% in the last 52 weeks. The beta is 0.39, so Gilead Sciences's price volatility has been lower than the market average.

Beta (5Y)	0.39
52-Week Price Change	+29.70%
50-Day Moving Average	137.19
200-Day Moving Average	121.10
Relative Strength Index (RSI)	52.03
Average Volume (20 Days)	5,018

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	2.92

Income Statement

In the last 12 months, Gilead Sciences had revenue of GBP 21.88 billion and earned 6.32 billion in profits. Earnings per share was 5.04.

Revenue	21.88B
Gross Profit	17.25B
Operating Income	8.78B
Pretax Income	7.28B
Net Income	6.32B
EBITDA	10.83B
EBIT	8.78B
Earnings Per Share (EPS)	5.04

Full Income Statement

Balance Sheet

The company has 7.14 billion in cash and 18.98 billion in debt, giving a net cash position of -9.62 billion.

Cash & Cash Equivalents	7.14B
Total Debt	18.98B
Net Cash	-9.62B
Net Cash Per Share	n/a
Equity (Book Value)	16.81B
Book Value Per Share	13.59
Working Capital	4.85B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 7.44 billion and capital expenditures -418.31 million, giving a free cash flow of 7.03 billion.

Operating Cash Flow	7.44B
Capital Expenditures	-418.31M
Free Cash Flow	7.03B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 78.84%, with operating and profit margins of 40.14% and 28.90%.

Gross Margin	78.84%
Operating Margin	40.14%
Pretax Margin	33.27%
Profit Margin	28.90%
EBITDA Margin	49.51%
EBIT Margin	40.14%
FCF Margin	32.12%

Dividends & Yields

This stock pays an annual dividend of 2.36, which amounts to a dividend yield of 1.60%.

Dividend Per Share	2.36
Dividend Yield	1.60%
Dividend Growth (YoY)	-1.78%
Years of Dividend Growth	n/a
Payout Ratio	47.04%
Buyback Yield	0.24%
Shareholder Yield	1.84%
Earnings Yield	4.59%
FCF Yield	5.10%

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Gilead Sciences has an Altman Z-Score of 3.9 and a Piotroski F-Score of 7.

Altman Z-Score	3.9
Piotroski F-Score	7